miRecule Enters into Strategic Collaboration with Sanofi to Accelerate Discovery and Development of a Best-in-Class Antibody-RNA Conjugate to Treat Facioscapulohumeral Muscular Dystrophy (FSHD)
by Ashwin Kulkarni | Oct 4, 2022 | New
Partnership combines miRecule’s unique RNA therapeutic discovery and conjugation platforms with Sanofi’s NANOBODY® technology to create a groundbreaking treatment for FSHD
miRecule will receive an upfront payment with potential future milestone payments of nearly $400 million, in addition to tiered royalties
Collaboration marks the first licensing transaction leveraging miRecule’s proprietary DREAmiRTM discovery platform, validating foundational science, and bolstering commitment to further expansion of the company’s RNA therapeutic pipeline
GAITHERSBURG, Maryland– October 4, 2022 – miRecule, Inc., an innovator of next-generation RNA therapeutics, today announced a strategic collaboration and exclusive license agreement with Sanofi to develop and commercialize a best-in-class antibody-RNA conjugate (ARC) for the treatment of facioscapulohumeral muscular dystrophy (FSHD). The collaboration marks miRecule’s first licensing transaction leveraging its proprietary DREAmiR platform.
FSHD is the second most common type of muscular dystrophy – affecting more than one million individuals worldwide with no approved treatments. Patients with causative genetic mutations experience lifelong deterioration of muscle function and progressive disability. The collaboration will combine miRecule’s anti-DUX4 RNA therapy (discovered through…
miRecule Names J&J Pharma Vet Fu-An Kang to Lead Growing Research Team
Published on :miRecule, Inc. (“miRecule”), an emerging biotech company focused on the development of cutting-edge RNA therapeutics, announced the hiring of Fu-An Kang, Ph.D. to serve as its Vice President of Research. Dr. Kang joins miRecule after serving for 6 years as the Senior Director of Chemistry at Abzena, a leading chemistry, biologics and antibody-drug conjugate (ADC) research organization.
miRecule Inc. closes $5.7 M to Create Breakthrough RNA Therapies for Cancer and Muscular Dystrophy
Published on :miRecule, Inc. (“miRecule”), an emerging biotech company focused on the development of cutting-edge RNA therapeutics, announced today it has closed over $5.7M in seed funding. The funding round was led by Alexandria Venture Investments, along with Boutique Venture Partners, Pathway Bioventures, Alumni Ventures Group, and national angel investors, with additional funding coming from the Maryland Momentum Fund and the FSHD Society. This funding includes a non-dilutive $2M Phase II SBIR grant from the National Cancer Institute.
NIH spinout raises millions to attack drug-resistant cancers with RNA. It has big plans.
Published on :Gaithersburg’s miRecule Inc. has raised $5.7 million in fresh funding, CEO Anthony Saleh told us Monday, positioning the company to start human testing for its lead candidate to treat head and neck cancer.
Gaithersburg’s miRecule Inc. closes $5.7M to Create Breakthrough RNA Therapies for Cancer and Muscular Dystrophy
Published on :miRecule, Inc. (“miRecule”), an emerging biotech company focused on the development of cutting-edge RNA therapeutics, announced today it has closed over $5.7M in seed funding. The funding round was led by Alexandria Venture Investments, along with Boutique Venture Partners, Pathway Bioventures, Alumni Ventures Group, and national angel investors, with additional funding coming from the Maryland Momentum Fund and the FSHD Society. This funding includes a non-dilutive $2M Phase II SBIR grant from the National Cancer Institute.
End of Year Update: 2020 Life Science Venture Capital Funding Roundup in the BioHealth Capital Region
Published on :This has certainly been a year unlike any other for BioHealth Capital Region (BHCR) life science companies of all sizes and kinds. Just a few months into 2020, the coronavirus pandemic swept the region, seriously disrupting, albeit temporarily, the best laid plans of aspiring founders, entrepreneurs, emerging startups, pre-clinical and more established, larger biohealth organizations in Virginia, Washington, D.C. and Maryland.
BioHealth Capital Region Startups Raised More Than $739M in 2019
Published on :BioHealth Capital Region Startups Raised More Than $739M in 2019 These 15 Biohealth Startups had a Banner Year, Setting Themselves Up for Success in 2020 The startup ecosystem in the [….]
Second Annual BioHealth Capital Investment Conference Expands With International Participation from New investors and Companies
Published on :BioHealth Capital Investment Conference
Three Examples That Show Why NCI is a Goldmine of Blockbuster Technologies for Commercialization
Published on :Three Examples of Commercializing Blockbuster Technologies from NCI
The 2nd Annual Tech Showcase Reflects New Culture at NCI & FNLCR
Published on :The 2nd Annual Tech Showcase Reflects New Culture at NCI & FNLCR When you hear the term “government research” do the words “entrepreneur”, “start-up”, “commercially relevant” or “industry partner” come to [….]